Although engagement of TLR3 and TLR4 pathways alone, for example, may not be sufficient to eradicate tumors, targeting these receptors could be considered as a supplement to therapy until mechanisms of glioma cell suppression on microglia are more clearly understood. This evidence concerns the gene TLR4 and central nervous system cancer.